Ticker Details
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
IPO Date:	January 31, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.55B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.58 | 2.65%
Avg Daily Range (30 D):	$0.98 | 3.52%
Avg Daily Range (90 D):	$0.85 | 3.22%

Institutional Daily Volume
Avg Daily Volume:	.59M
Avg Daily Volume (30 D):	1.5M
Avg Daily Volume (90 D):	1.58M

Trade Size
Avg Trade Size (Sh.):	67
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	62

Institutional Trades
Total Institutional Trades:	7,624
Avg Institutional Trade:	$2.95M
Avg Institutional Trade (30 D):	$4.12M
Avg Institutional Trade (90 D):	$5.11M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.85M
Avg Closing Trade (30 D):	$9.8M
Avg Closing Trade (90 D):	$11.55M
Avg Closing Volume:	101.24K

News

Jun 19, 2026 @ 8:30 PM Ultragenyx Reports Inducement Grant Under Nasdaq L... Source: Na

Apr 6, 2026 @ 2:51 PM ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire,... Source: Bragar Eagel & Squire, P.C.

Apr 5, 2026 @ 11:29 PM TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL... Source: Rosen Law Firm

Apr 5, 2026 @ 10:37 PM RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUN... Source: Rosen Law Firm

Apr 1, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx... Source: Bronstein, Gewirtz & Grossman Llc

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-5.83	$-.9	$-1.84
Diluted EPS	$-5.83	$-.9	$-1.84
Revenue	$717.21M	$214M	$136M
Gross Profit
Net Income / Loss	$-585.97M	$-92M	$-185M
Operating Income / Loss	$-528.17M	$-75M	$-169M
Cost of Revenue
Net Cash Flow	$-48M	$-296M	$M
PE Ratio

Splits
Jan 17, 2014	15:47